

FramingHam

on systemic fungal infections

Aspergillosis coinfection in patients with proven mucormycosis

Medical Mycology, 2024 August 2; 62(8):myae081

Global guideline for the diagnosis and management of cryptococcosis:
an initiative of the ECMM and ISHAM in cooperation with the ASM

The Lancet Infectious Diseases, 2024 August; 24(8):e495–512

Factors associated with poor clinical and microbiologic outcomes
in *C. Auris* bloodstream infection: a multicenter retrospective cohort study

Clinical Infectious Diseases, 2024 August 13; Epub ahead of print

Environmental hot spots and resistance-associated application practices for
azole-resistant *Aspergillus fumigatus*, Denmark, 2020–2023

Emerging Infectious Diseases, 2024 August; 30(8):1531–41

Insights from three pan-European multicentre studies on invasive *Candida* infections
and outlook to ECMM *Candida* IV

Mycopathologia, 2024 August 1; 189(4):70

The impact of the fungal priority pathogens list on medical mycology:
a northern European perspective

Open Forum Infectious Diseases, 2024 July 1; 11(7):ofae372

Antifungal drug usage in European neonatal units:
a multicenter weekly point prevalence study

The Pediatric Infectious Disease Journal, 2024 June 25; Epub ahead of print

and more...

ISSUE 3, 2024

CURRENT TITLES

Framingham *on amyloidosis*
 Framingham *on atherosclerosis*
 Framingham *on benign
 haematology*
 Framingham *on breast cancer*
 Framingham *on dermatology*
 Framingham *on gastroenterology*
 Framingham *on haematological
 malignancies*
 Framingham *on HIV/AIDS*
 Framingham *on infectious diseases*
 Framingham *on lung cancer*
 Framingham *on multiple myeloma*
 Framingham *on multiple sclerosis*
 Framingham *on neurology*
 Framingham *on ophthalmology*
 Framingham *on osteoporosis*
 Framingham *on ovarian cancer*
 Framingham *on psychiatry*
 Framingham *on rheumatology*
 Framingham *on urology*
and many more...

DISCLAIMER

The abstracts in this publication are prepared with care to reflect the views expressed by the author or authors of the original source material. These views are not necessarily those of the publisher or the sponsor. While every care is taken to avoid errors, these cannot always be avoided; readers are advised to independently validate any data and recommendations contained herein before acting on this information. The publisher and the sponsor disclaim any responsibility or liability for the accuracy of such information.

ADVISORY BOARD

Paul E. Verweij, MD PhD
 Professor of Clinical Mycology,
 Consultant Microbiologist &
 Head of the Department of
 Medical Microbiology,
 University Medical Center
 Nijmegen,
 and Nijmegen University Center
 for Infectious Diseases,
 Nijmegen, the Netherlands

OUR PURPOSE

The Framingham series of publications is designed to meet clinical specialists' need for a reliable guide to the most important articles appearing in their field.

Each issue presents an authoritative selection from the recently published literature, with the emphasis on evidence-based medicine. Articles are recommended for inclusion by Framingham's editorial office and an advisory board headed by key opinion leaders in the relevant clinical area.

Framingham's team of medical writers prepares original abstracts of these articles, in a structured format that presents the main points at a glance. Our aim is to convey the essence of each article in a concise but readable style.

Issues are published every three to six months.

Framingham**Editor**

Kathy Croom

Medical Writers (this issue)

Stephen Bartlett
 Jane Grills
 Kathy Longley
 David Newton
 Kevin West

Art Design

Jan van Halm

Layout and Printing

Drukmeesters,
 Zwijndrecht, the Netherlands

Publishing Director

Evelien Enter

Publisher

Waldemar H.G. Dobrowolski

Framingham bv

Postbus 1593
 1200 BN Hilversum
 The Netherlands
www.framinghampublishers.com

Framingham *on systemic fungal
 infections* is supported by
Gilead Sciences Netherlands BV,
 Amsterdam, the Netherlands

© 2024 Framingham bv

ASPERGILLOSIS COINFECTION IN PATIENTS WITH PROVEN MUCORMYCOSIS

Medical Mycology, 2024 August 2; 62(8):myae081

AUTHORS: RA SH, KIM JY, SONG JS, JANG HM, CHANG E, BAE S, JUNG J, KIM MJ, CHONG YP, LEE SO, CHOI SH, KIM YS, KIM SH

CENTRES: DEPARTMENT OF INFECTIOUS DISEASES; AND DEPARTMENT OF PATHOLOGY, ASAN MEDICAL CENTER, UNIVERSITY OF ULSAN COLLEGE OF MEDICINE, SEOUL, REPUBLIC OF KOREA

BACKGROUND & AIM: Mucormycosis and aspergillosis are particularly challenging to diagnose and manage because of their similar risk factors and clinical manifestations. Fungal cultures often have low sensitivity, while microscopic findings may be inconsistent, making it difficult to differentiate between them. Several studies have reported cases of mucormycosis and aspergillosis coinfection, and emphasised the importance of distinguishing between them to ensure optimal antifungal therapy. However, this has not yet been investigated systematically. The aim of the current study was therefore to assess aspergillosis coinfection in patients with proven mucormycosis.

STUDY DESIGN: Retrospective review of medical records.

ENDPOINT: Aspergillosis coinfection.

METHOD: The study included 67 adults with proven mucormycosis diagnosed at a tertiary hospital between 2007 and 2023, whose medical records were reviewed, and for whom formalin-fixed paraffin-embedded (FFPE) tissue sections were available for analysis. Proven mucormycosis was defined as the identification of mucormycosis-causing agents from sterile specimens and/or positive mucormycosis immunohistochemistry (IHC) findings. IHC was performed on the tissue sections, and the slides were examined by an experienced pathologist for

the identification of aspergillosis coinfection. In addition, polymerase chain reaction (PCR) assays were performed to detect *Aspergillus*- and Mucorales-specific DNA.

RESULTS: Analysing fungal cultures from sterile and non-sterile sites identified *Aspergillus* species growth in nine patients (13%), from two sterile and seven non-sterile cultures. Fungal PCR analyses of the FFPE tissue sections identified Mucorales-specific results in 26 patients (39%), and *Aspergillus*-specific results in five patients (7%). Eight patients (12%) had both positive *Aspergillus*- and Mucorales-specific PCR results. Combining cultures and PCR results, a total of 21 out of 67 patients (31%) with proven mucormycosis had evidence of aspergillosis coinfection. The prevalence of positive blood or bronchoalveolar lavage fluid galactomannan results was higher in patients with coinfection than in those with mucormycosis only (67% versus 37%, $p=0.024$). There were no significant differences in 30-, 90- or 180-day mortality between the two groups

CONCLUSIONS: Molecular and/or microbiological evidence of aspergillosis coinfection was identified in almost a third of patients with proven mucormycosis. The use of multiple diagnostic methods is needed to identify patients with coinfections, to ensure optimal antifungal therapy.

GLOBAL GUIDELINE FOR THE DIAGNOSIS AND MANAGEMENT OF CRYPTOCOCCOSIS: AN INITIATIVE OF THE ECMM AND ISHAM IN COOPERATION WITH THE ASM

The Lancet Infectious Diseases, 2024 August; 24(8):e495–512

AUTHORS: CHANG CC, HARRISON TS, BICANIC TA, ET AL.

CENTRES FOR CORRESPONDENCE: DEPARTMENT OF INFECTIOUS DISEASES, ALFRED HOSPITAL, MELBOURNE, VICTORIA, AUSTRALIA; DIVISION OF INFECTIOUS DISEASES, DEPARTMENT OF MEDICINE, DUKE UNIVERSITY MEDICAL CENTER, DURHAM, NORTH CAROLINA, USA

BACKGROUND & AIM: Cryptococcosis is a disseminated invasive fungal infection associated with significant morbidity and mortality. It commonly affects the lungs and central nervous system (CNS), but disseminated disease can involve other organs while appearing to be localized. The disease is particularly common in low- and middle-income countries, including sub-Saharan Africa, where the main risk factor is HIV/AIDS. The most severe form is cryptococcal meningitis, which has a mortality rate of 24–47% at 10 weeks. This article presents a global guideline for the diagnosis and management of cryptococcosis.

ARTICLE TYPE: Clinical guideline.

FINDINGS: The choice and duration of antifungal treatment for cryptococcosis should depend on the specific clinical syndrome, which can be divided into CNS, disseminated disease, isolated pulmonary disease and direct skin inoculation. In high-income countries, the optimal induction therapy for cryptococcal meningitis, disseminated cryptococcosis and severe isolated pulmonary cryptococcosis is liposomal amphotericin B at a dose of 3–4 mg/kg per day plus flucytosine 25 mg/kg four times a day. In low-income settings (where antifungal access, adverse effects and monitoring present challenges), the optimal induction therapy for HIV-associated cryptococcal meningitis is a single dose of

liposomal amphotericin B 10 mg/kg, plus 14 days of flucytosine 25 mg/kg four times a day and fluconazole 1200 mg per day. However, there is no clinical trial evidence for this regimen in patients with non-HIV-associated cryptococcal meningitis or other non-CNS cryptococcosis syndromes. There have been no trials of consolidation or maintenance therapy in recent years, but fluconazole 400–800 mg per day for 8 weeks is recommended for consolidation, and fluconazole 200 mg per day for up to 12 months for maintenance.

It is important to provide the most effective antifungal therapy possible to optimize outcomes, and to monitor for and minimize potential toxic effects, in order to avoid having to stop treatment or switch to an inferior regimen unnecessarily. Clinical relapse should be expected and monitored for, so the cause can be properly investigated. Adherence to therapy and the development of drug–drug interactions should also be evaluated throughout treatment. Other recommendations include ensuring that raised intracranial pressure is managed by therapeutic lumbar puncture or surgical decompression as necessary, and investigating potential underlying immunodeficiencies (particularly HIV infection).

CONCLUSIONS: This global guideline provides recommendations on the management of cryptococcosis, but should be adapted to suit local practices.

FACTORS ASSOCIATED WITH POOR CLINICAL AND MICROBIOLOGIC OUTCOMES IN *C. AURIS* BLOODSTREAM INFECTION: A MULTICENTER RETROSPECTIVE COHORT STUDY

Clinical Infectious Diseases, 2024 August 13; Epub ahead of print

AUTHORS: JIMENEZ A, ROSA R, AYOUB S, GURAN R, ARENAS S, VALENCIA N, STABILE JC, ESTEPA AT, PAREKH DJ, FERREIRA T, GERSHENGORN HB, PRABAKER KK, ECKARDT PA, ZAHN M, ABBO LM, SHUKLA BS
CENTRE FOR CORRESPONDENCE: DEPARTMENT OF PUBLIC HEALTH SCIENCES, MILLER SCHOOL OF MEDICINE, UNIVERSITY OF MIAMI HEALTH SYSTEM, MIAMI, FLORIDA, USA

BACKGROUND & AIM: *Candida auris* is a high-priority pathogen with an increasing incidence worldwide and a propensity for invasive infections. Up to 25% of intensive care unit patients with *C. auris* colonization will develop *C. auris* bloodstream infections (BSIs). This study evaluated clinical outcomes of patients with *C. auris* BSI, and explored risk factors for poor outcomes.

STUDY DESIGN: Multicentre, retrospective cohort study.


ENDPOINTS: The coprimary endpoints were all-cause mortality during facility admission and blood culture clearance. Time to BSI index culture and time from BSI index culture to death were also investigated.

METHOD: Demographic, clinical and microbiological data were obtained for adult patients with *C. auris* BSI between

2017 and 2022 from two US regions. These were analysed by multivariate logistic regression to determine risk factors for all-cause mortality during facility admission, and blood culture clearance. Patients were stratified by severity of illness based on Pitt bacteraemia score (0, 1–4, 5–8).

RESULTS: Among 187 patients with *C. auris* BSI (43.9% female, 55.6% aged >65 years), the all-cause mortality rate was 54.6%. Among 142 patients with evaluable data, 66.9% achieved blood culture clearance. Bedbound patients (i.e. low palliative performance scale score on admission) and patients with feeding tubes tended to have higher Pitt scores at the time of the index culture. Most patients developed BSI (indicated by index culture) within 30 days of facility admission (see figure), and over half of deaths following BSI occurred within 45 days of the index culture. Pitt bacteraemia score at onset of *C. auris* BSI was associated with mortality (odds ratio 1.19 per 1-point increase, $p=0.037$). Haemodialysis was also associated with mortality (OR 3.08, $p=0.013$), as well as with a reduced likelihood of blood culture clearance (OR 0.15, $p<0.001$).

CONCLUSIONS: Among patients with *C. auris* BSI, Pitt bacteraemia score at onset may help identify those at greatest risk of dying. Prophylactic anti-infection measures could mitigate poor outcomes in those receiving haemodialysis.



ENVIRONMENTAL HOT SPOTS AND RESISTANCE-ASSOCIATED APPLICATION PRACTICES FOR AZOLE-RESISTANT *ASPERGILLUS FUMIGATUS*, DENMARK, 2020–2023

Emerging Infectious Diseases, 2024 August; 30(8):1531–41

AUTHORS: ARENDRUP MC, HARE RK, JØRGENSEN KM, BOLLMANN UE, BECH TB, HANSEN CC, HEICK TM, JØRGENSEN LN

CENTRES: RIGSHOSPITALET, COPENHAGEN UNIVERSITY; STATENS SERUM INSTITUT; GEOLOGICAL SURVEY OF DENMARK AND GREENLAND, COPENHAGEN; AND AARHUS UNIVERSITY, FLAKKEBJERG, SLAGELSE, DENMARK

BACKGROUND & AIMS: Increasing evidence suggests that selection of azole-resistant *Aspergillus fumigatus* (ARAF) can occur in the environment. In Denmark, nationwide surveillance of clinical *A. fumigatus* between 2018 and 2020 found environmental-origin resistance mutations TR₃₄/L98H or TR₄₆/Y121F/T289A present in 3.6% of clinical isolates. The aims of the current study were to perform extensive environmental sampling to determine hotspots for ARAF, the effect of azole concentrations on resistance development, characterize resistance mechanisms and molecular genotypes, and investigate the potential of various azole fungicides to select for ARAF.

STUDY DESIGN: Environmental sampling study.

ENDPOINT: ARAF in environmental samples.

METHOD: A total of 366 samples were collected from agricultural fields, flowerbeds in parks and private gardens, flower and potato production soil, compost soil/heaps, animal bedding/manure heaps and wood paint-associated soil in Denmark between 2020 and 2023. *A. fumigatus* isolates identified in the samples underwent azole-resistance screening, and any ARAF underwent molecular characterization and genotyping. Azole concentrations used on the environmental samples were determined for eight azole fungicides. Microcosmos and

field experiments assessed the potential of various azole fungicides to select for ARAF.

RESULTS: ARAF was found in 20% of the 366 samples (16% TR₃₄/L98H and 4% TR₄₆/Y121F/T289A), and in 4.2% of the 4538 *A. fumigatus* isolates identified. ARAF was found in all of the different environmental sample types, with the highest proportions found in flower- and compost-related samples. The proportions of ARAF in the samples did not correlate with azole-fungicide application concentrations. Using genotyping, a cluster of TR₃₄/L98H was identified that was widely distributed across the country and was found in both clinical and environmental isolates. In the field experiment, poor growth of *A. fumigatus* was observed and there was no change in the proportions of ARAF between prespraying and postspraying samples. However, the microcosmos experiments indicated that some azole fungicides may encourage selection of ARAF in soil, as tebuconazole caused sustained complete inhibition and prothioconazole partial inhibition of wild-type *A. fumigatus* but not of ARAF.

CONCLUSIONS: There is evidence of ARAF in a wide range of environmental samples in Denmark, with compost, flowerbeds and flower production being the main hotspots. Increasing resistance rates will challenge patient management and could possibly be slowed by prioritizing the use of *A. fumigatus*-active azole fungicides.

INSIGHTS FROM THREE PAN-EUROPEAN MULTICENTRE STUDIES ON INVASIVE CANDIDA INFECTIONS AND OUTLOOK TO ECMM CANDIDA IV

Mycopathologia, 2024 August 1; 189(4):70

AUTHORS: WOLFGRUBER S, SEDIK S, KLINGSPOR L, TORTORANO A, GOW NA, LAGROU K, GANGNEUX JP, MAERTENS J, MEIS JF, LASS-FLÖRL C, ARIKAN-AKDAGLI S, CORNELI OA, HOENIGL M
CENTRE FOR CORRESPONDENCE: DIVISION OF INFECTIOUS DISEASES, DEPARTMENT OF INTERNAL MEDICINE, MEDICAL UNIVERSITY OF GRAZ, GRAZ, AUSTRIA

BACKGROUND & AIM: The European Confederation of Medical Mycology (ECMM) conducted three prospective studies across multiple European countries between 1997 and 2022 looking at different features of invasive *Candida* infections, including clinical and microbiological characteristics, antifungal therapy and clinical outcomes. This article reviews key findings.

ARTICLE TYPE: Review.

FINDINGS: *Candida* I (which included 2089 patients with candidaemia based on hospital records) identified *C. albicans* as the most common pathogen (56%), although the incidence of non-*albicans* infections was high versus previous studies. *Candida* II (779 surgical patients with invasive candidiasis in the intensive care unit, ICU) found that most (80.5%) developed *Candida* infections >48 hours after ICU admission (i.e. ICU-acquired infections). In *Candida* III (632 patients with culture-proven candidaemia), the incidence of *C. albicans* infection was 46% and the 90-day mortality rate was 43%. The study identified increasing age, ICU admission, high Charlson comorbidity index score and *C. tropicalis* infection as independent predictors of mortality. First-line echinocandin treatment was associated with improved survival, but also a longer hospital stay due to its parenteral administration.

Risk factors for invasive *Candida* infections identified by the studies included

advanced age, major surgery, ICU admission, solid and haematological malignancies, solid-organ transplantation, corticosteroid use, total parenteral nutrition, central venous catheters and burns. Other risk factors identified in *Candida* II (ICU patients) included recent use of broad-spectrum antibiotics, rheumatological disease, recent steroid use and dialysis. The mortality rate was high in all three studies, with a crude 30-day mortality rate of around 38%. *Candida* III also calculated an attributable mortality of 18.1%.

In *Candida* I, 84.5% of patients received antifungal therapy (primarily fluconazole or amphotericin B). In *Candida* II, 16.5% of post-surgical ICU patients received antifungal prophylaxis, most often fluconazole, which was also the most frequent initial antifungal treatment, followed by caspofungin. Antifungal prophylaxis (mainly fluconazole) was also administered to 16.5% of patients in *Candida* III, while echinocandins were the most common initial treatment (56%) and were associated with a lower mortality rate than other antifungals.

CONCLUSIONS: Key findings of the ECMM *Candida* studies include shifts in species distribution, with an increase in non-*albicans* species, and persistently high mortality rates. The article also looks ahead to the forthcoming *Candida* IV study, which will focus on non-*albicans* species.

TREATMENT OUTCOMES AMONG PATIENTS WITH A POSITIVE *CANDIDA* CULTURE CLOSE TO RANDOMIZATION RECEIVING REZAFUNGIN OR CASPOFUNGIN IN THE RESTORE STUDY

Clinical Infectious Diseases, 2024 July 10; Epub ahead of print

AUTHORS: SORIANO A, HONORE PM, CORNELLY OA, CHAYAKULKEEREE M, BASSETTI M, HAIHUI H, DUPONT H, KIM YK, KOLLEF M, KULLBERG BJ, MANAMLEY N, PAPPAS P, PULLMAN J, SANDISON T, DIGNANI C, VAZQUEZ JA, THOMPSON III GR
CENTRE FOR CORRESPONDENCE: UNIVERSITY OF CALIFORNIA DAVIS MEDICAL CENTER, SACRAMENTO, CALIFORNIA, USA

BACKGROUND & AIM: In the ReSTORE study, a novel, once-weekly echinocandin, rezafungin, was non-inferior to caspofungin in terms of 30-day all-cause mortality and 14-day global cure rate in patients with candidaemia and/or invasive candidiasis. A pre-planned subgroup analysis of ReSTORE participants who had a positive *Candida* culture close to randomization has now been reported.

STUDY DESIGN: Subgroup analysis of a multicentre, randomized, double-blind, double-dummy trial.

ENDPOINTS: Thirty-day all-cause mortality, 14-day global cure rate, 5- and 14-day mycological eradication rates, median time to negative blood culture, and adverse events.

METHOD: The original study randomized adults with candidaemia and/or invasive candidiasis to treatment with once-weekly intravenous rezafungin (400 mg on day 1, then 200 mg) or once-daily intravenous caspofungin (70 mg on day 1, then 50 mg). This subgroup analysis focused on

participants who had a positive *Candida* blood culture between 12 hours before and 72 hours after randomization, or a positive culture from another normally sterile site between 48 hours before and 72 hours after randomization.

RESULTS: The analysis included 38 rezafungin recipients and 46 caspofungin recipients. The 30-day all-cause mortality rate, 14-day global cure rate and 14-day mycological eradication rate were similar in both subgroups (table). There was a non-significant trend towards a higher 5-day mycological eradication rate with rezafungin versus caspofungin (table). There was also a non-significant trend towards a shorter median time to negative blood culture with rezafungin versus caspofungin (23.9 versus 60.5 hours, nominal $p=0.094$). Negative blood culture rates were higher in rezafungin recipients versus caspofungin recipients at 24 hours after treatment initiation (55.2% versus 27.3%, nominal $p=0.0162$) but not at 48 hours after treatment initiation (58.6% versus 43.8%, nominal $p=0.2460$). The nature, incidence and severity of adverse events were similar in the two subgroups.

CONCLUSIONS: Among ReSTORE participants with candidaemia and/or invasive candidiasis with a positive *Candida* blood culture close to randomization, rezafungin showed similar efficacy to caspofungin. Rezafungin appeared to provide more rapid clearance of *Candida* infection.

Outcomes with rezafungin versus caspofungin in ReSTORE participants with candidaemia and/or invasive candidiasis with a positive *Candida* blood culture close to randomization

	Rezafungin (%)	Caspofungin (%)	Treatment difference, % points (95% confidence interval)
30-day all-cause mortality rate	26.3	21.7	4.6 (−13.7 to 23.5)
14-day global cure rate	55.3	50.0	5.3 (−16.1 to 26.0)
5-day mycological eradication rate	71.1	50.0	21.1 (−0.2 to 40.2)
14-day mycological eradication rate	63.2	54.3	8.8 (−12.4 to 29.0)

THE IMPACT OF THE FUNGAL PRIORITY PATHOGENS LIST ON MEDICAL MYCOLOGY: A NORTHERN EUROPEAN PERSPECTIVE

Open Forum Infectious Diseases, 2024 July 1; 11(7):ofae372

AUTHORS: ARENDRUP MC, ARMSTRONG-JAMES D, BORMAN AM, DENNING DW, FISHER MC, GORTON R, MAERTENS J, MARTIN-LOECHES I, MEHRA V, MERCIER T, PRICE J, RAUTEMAA-RICHARDSON R, WAKE R, ANDREWS N, WHITE PL
CENTRE FOR CORRESPONDENCE: PUBLIC HEALTH WALES MYCOLOGY REFERENCE LABORATORY AND CARDIFF UNIVERSITY CENTRE FOR TRIALS RESEARCH, UNIVERSITY HOSPITAL OF WALES, CARDIFF, UK

BACKGROUND & AIM: Fungal diseases affect more than 1 billion people globally and antifungal resistance is increasing. In response to this widely overlooked global public health concern, the World Health Organization published the first fungal priority pathogens list (FPPL) in 2022, with the aim of strengthening the global response to fungal diseases and antifungal resistance by focusing research priorities and driving policy interventions. The authors reviewed the impact of FPPL on regional clinical practice by conducting a workshop with key experts from Northern Europe.

ARTICLE TYPE: Review.

FINDINGS: The FPPL has highlighted the challenge of estimating the global burden of fungal diseases and antifungal resistance due to limited surveillance, diagnostic coverage and routine antifungal resistance testing. Current diagnostic methodologies are limited as they require a high level of experience for identifying fungi and can take up to 30 days. Molecular testing is more rapid and sensitive but there are few tests widely available commercially. Broadening access to mycology laboratories and to affordable, high-quality diagnostics is needed to improve fungal disease surveillance as well as early and accurate diagnosis.

Improved surveillance also relies on adequate knowledge and education regarding the clinical presentation of fungal infections

and risk factors for infection. Publication of the FPPL is an important first step in raising awareness of fungal pathogens, but increased coverage of fungal diseases in the medical curriculum is needed, along with joint training programmes to educate both clinicians and laboratory technicians in fungal disease management. There is also a need to encourage scientists to specialize in mycology, and for sustainable investment in research and development.

Strategies to tackle antifungal resistance should include increased routine resistance testing, efficient stewardship programmes to limit inappropriate use of antifungal agents, and the One Health approach that can mitigate the use of antimicrobials in the environment. In Northern Europe there is widespread air exposure to azole-resistant *Aspergillus fumigatus*, which accounts for around 40% of resistant infections.

The FPPL is also important for strengthening local guidance on tackling fungal diseases and improving healthcare systems to promote evidence-based therapy.

CONCLUSIONS: The FPPL is a major step in increasing awareness of fungal pathogens, and highlights the importance of strengthening laboratory capacity and surveillance, improving education, and encouraging sustainable investment in research and development and in public health interventions.

THE ASPERGILLUS GALACTOMANNAN AG VIRCLIA® MONOTEST AND THE SÖNA ASPERGILLUS GALACTOMANNAN LATERAL FLOW ASSAY SHOW COMPARABLE PERFORMANCE FOR THE DIAGNOSIS OF INVASIVE ASPERGILLOSIS

Mycoses, 2024 August; 67(8):e13782

AUTHORS: KÜPPER C, ERB TM, TRÄGER J, MEINTKER L, VALENZA G, BOGDAN C, HELD J

CENTRES: MIKROBIOLOGISCHES INSTITUT–KLINISCHE MIKROBIOLOGIE, IMMUNOLOGIE UND HYGIENE; DEPARTMENT FÜR HÄMATOLOGIE/ONKOLOGIE, MEDIZINISCHE KLINIK 5, UNIVERSITÄTSKLINIKUM ERLANGEN UND FRIEDRICH-ALEXANDER-UNIVERSITÄT (FAU) ERLANGEN-NÜRNBERG; FAU PROFILE CENTER FOR IMMUNOMEDICINE, FAU ERLANGEN-NÜRNBERG, ERLANGEN, GERMANY

BACKGROUND & AIM: Rapid diagnosis is key to reducing mortality in patients with invasive aspergillosis (IA), but existing galactomannan (GM) enzyme immunoassays (EIA) can be a diagnostic bottleneck. The aim of this study was to evaluate the performance of two rapid diagnostic tests – a GM lateral flow assay (GM-LFA) and a recently introduced chemiluminescence immunoassay (GM-Monotest).

STUDY DESIGN: Laboratory study.

ENDPOINTS: Diagnostic performance.

METHOD: The rapid tests were compared on the basis of their performance in analysing retained serum, bronchoalveolar lavage fluid (BALF) or cerebrospinal fluid (CSF) samples from two patient cohorts: (1) patients who had undergone allogeneic haematopoietic stem-cell transplantation (alloHSCT) during 2010 and (2) a cross-sectional cohort of all patients with proven or probable IA diagnosed between 2015 and 2020 at the university hospital in Erlangen. Positive samples were confirmed by re-testing of a second aliquot of the same sample. Testing by the GM-LFA method was carried out with visual evaluation and using a digital cube reader, while for the GM-Monotest an automated analyser was used.

RESULTS: The alloHSCT cohort comprised 101 patients (one proven IA, three

probable IA on the basis of GM-EIA) with 527 samples (all sera). A first round of testing with the GM-Monotest and GM-LFA led to 18 and 70 of these sera being rated positive, respectively. Testing of a second aliquot resulted in two (11.1%) of the GM-Monotest samples and 32 (45.7%) of the GM-LFA samples being reclassified as negative. With the GM-LFA assay, 26.3% of sera gave a reading in an “equivocal” zone, where the manufacturer recommends re-testing. Comparison of their receiver operating characteristic curves showed no significant difference between the GM-Monotest and GM-LFA (area under the receiver operating characteristic curve 0.985 versus 0.988, $p=0.239$) and they both showed good agreement with GM-EIA results. The cross-sectional cohort included 59 patients (six proven IA, 53 probable IA) who generated 184 samples (96 sera, 83 BALF, five CSF). Again, performance of the two rapid assays correlated well with GM-EIA, with Cohen’s kappa being 0.89 for the GM-Monotest and 0.82 for the GM-LFA. Both tests had significantly better sensitivity when used to test BALF versus serum.

CONCLUSIONS: The GM-LFA and GM-Monotest rapid diagnostic tests performed similarly to GM-EIA but, due to poor reproducibility, positive GM-LFA tests should always be confirmed by re-testing.

ANTIFUNGAL DRUG USAGE IN EUROPEAN NEONATAL UNITS: A MULTICENTER WEEKLY POINT PREVALENCE STUDY

The Pediatric Infectious Disease Journal, 2024 June 25; Epub ahead of print

AUTHORS: CHORAFI E, IOSIFIDIS E, OLETTA A, ET AL.

CENTRE FOR CORRESPONDENCE: INFECTIOUS DISEASES UNIT, 3RD DEPARTMENT OF PEDIATRICS, ARISTOTLE UNIVERSITY SCHOOL OF MEDICINE, HIPPOKRATION HOSPITAL, THESSALONIKI, GREECE

BACKGROUND & AIM: For critically ill neonatal and paediatric patients, invasive fungal infections represent a major threat. Difficulties in diagnosis in this population and the high morbidity and mortality of invasive fungal infections can lead to increased or excessive antifungal prescribing in neonatal units, and antifungal stewardship programmes are warranted. However, there are limited data on antifungal prescribing patterns for neonatal patients, with published data restricted to single-centre or single-country studies or to 1-day recordings. The aim of this study was to assess longitudinal antifungal usage in neonatal units in Europe.

STUDY DESIGN: Prospective, weekly point-prevalence study.

ENDPOINTS: Antifungal indications, patient risk factors and antifungal regimens.

METHOD: The study was carried out in 18 hospitals across eight European countries during a 12-week period in 2020. The study population comprised all neonatal patients who received systemic antifungal treatment. At the start of the study, ward-specific data on antifungal practices were collected; during the study period, ward- and patient-specific data were collected weekly.

RESULTS: Of the 27 participating neonatal units, 15 (56%) implemented antifungal prophylaxis, with the majority of courses

targeted to premature neonates with low (<1500 g) or very low (<1000 g) birth-weight plus additional risk factors (e.g. mechanical ventilation). An antifungal stewardship policy was in place in 44% of the neonatal units. Antifungal drugs were given to 174 patients. The median weekly proportion of patients prescribed antifungals was 10.5% (range 6.9–12.6%). Prophylaxis was the indication for prescribing 135 of the 174 antifungal courses (78%), while 39 courses (22%) were prescribed as treatment (69% empirical, 10% pre-emptive, 21% targeted). The most frequently prescribed systemic agent was fluconazole, which was used both for prophylaxis (98.5% of courses) and treatment (38.5% of courses). The most common risk factors in neonates given prophylaxis were premature birth (88%), mechanical ventilation (81%) and central vascular catheterization (66%), whereas only 41% of courses were in patients with gestational age <28 weeks and only 36% were in patients with a birthweight <1000 g. Late-onset sepsis was the most common reason for empirical treatment (63%). All eight of the targeted antifungal courses were prescribed to treat invasive candidiasis.

CONCLUSIONS: In European neonatal units, antifungal usage appeared to be mainly driven by prophylaxis and empirical treatment. In both these settings, fluconazole was the most frequently prescribed antifungal agent.

EUROPEAN STUDY OF CEREBRAL ASPERGILLOSIS TREATED WITH ISAVUCONAZOLE (ESCAI): A STUDY BY THE ESCMID FUNGAL INFECTION STUDY GROUP

Clinical Infectious Diseases, 2024 July 30; Epub ahead of print

AUTHORS: SERRIS A, RAUTEMAA-RICHARDSON R, LARANJINHA J, ET AL., FOR THE ESCAI STUDY GROUP

CENTRE FOR CORRESPONDENCE: CENTRE FOR INFECTIOUS DISEASES AND TROPICAL MEDICINE, HÔPITAL UNIVERSITAIRE NECKER-ENFANTS MALADES, ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS, UNIVERSITÉ DE PARIS, PARIS, FRANCE

BACKGROUND & AIM: Voriconazole is an established first-line treatment for cerebral aspergillosis (CA), a rare but often fatal form of invasive aspergillosis, but it has significant toxicities and interacts with many drugs. Isavuconazole shows less toxicity and fewer drug–drug interactions than voriconazole, but it was only approved in 2017, and its efficacy and safety are not as well documented. The aim of this study was to evaluate the efficacy and safety of isavuconazole in the treatment of CA and to compare survival data with that for voriconazole.

STUDY DESIGN: Multicentre, retrospective cohort study.

ENDPOINTS: Primary: survival rate 12 weeks after starting isavuconazole. Secondary: overall response to therapy and overall rate of survival.

METHOD: The study analysed data for European patients with proven or probable CA diagnosed between 2014 and 2022 and treated at any point with isavuconazole, whose characteristics, treatment and outcomes were recorded in the ESCAI study database. Survival data were compared with patients in the French national cohort study (CEREALS) database of CA patients diagnosed between 2006 and 2018, who were predominantly treated with voriconazole. For survival analyses, inverse probability of treatment weighting was used to balance patient prognostic factors.

RESULTS: The ESCAI study included 40 patients (25 proven, 15 probable CA). Ten (25%) received isavuconazole as first-line treatment, for a median duration of 64 days; in nine cases, it was eventually combined with liposomal amphotericin B or an echinocandin. The other 30 patients were switched to isavuconazole after treatment with one or more other antifungals for a median 65 days (voriconazole alone or in combination regimens in 18 patients). The median duration of second-line isavuconazole was 159 days, and it was initially given as monotherapy in 24/30 patients. Overall, 18/40 (45%) patients showed a complete response to isavuconazole, 5/40 (12.5%) had a partial response, 6/40 (15%) had stable disease and in 11/40 (27.5%) the disease progressed. After 12 weeks of isavuconazole treatment, overall mortality was 18%. Only the use of therapeutic drug monitoring was predictive of lower mortality ($p=0.04$). After 1 year, weighted survival of those given isavuconazole as first-line therapy was similar to those given voriconazole (hazard ratio 0.94, 95% confidence interval 0.38–2.32). Among the 40 isavuconazole recipients, two developed hepatotoxicity and one developed acute kidney failure.

CONCLUSION: Isavuconazole was similarly effective to voriconazole at preventing mortality in the first-line treatment of CA, with an acceptable safety profile.

ISAVUCONAZOLE AS PROPHYLAXIS AND THERAPY FOR INVASIVE FUNGAL DISEASES: A REAL-LIFE OBSERVATIONAL STUDY

Journal of Antimicrobial Therapy, 2024 August 1; 79(8):1801–10

AUTHORS: ERGÜN M, JANSEN AM, HILBRANDS LB, DE KORT E, KUNST H, REIJERS MH, SCHOUTEN JA, VERWEIJ PE, BRÜGGEMANN RJ

CENTRE FOR CORRESPONDENCE: RADBOUDUMC-CWZ CENTER OF EXPERTISE FOR MYCOLOGY, RADBOUD UNIVERSITY MEDICAL CENTER, NIJMEGEN, THE NETHERLANDS

BACKGROUND & AIM: Treating invasive aspergillosis (IA) with triazoles is challenging as patients often experience drug side effects and drug–drug interactions, which can lead to switches in therapy. Isavuconazole is a newer azole with a favourable drug interaction profile and similar efficacy to voriconazole. However, there are limited real-world data on isavuconazole. The aim of this study was to describe the usage pattern of isavuconazole in clinical practice.

STUDY DESIGN: Retrospective observational study.

ENDPOINTS: Indication for isavuconazole use; efficacy and safety; isavuconazole exposure (average area under the concentration curve for 0–24 hours during the first 7 days of treatment, AUC_{24}).

METHOD: The cohort comprised 99 patients treated with isavuconazole in a tertiary care hospital in the Netherlands between 2017 and 2021. Patient-level therapeutic drug monitoring data, and efficacy

and safety data were analysed. Individual isavuconazole exposure was estimated using non-linear mixed-effects modelling and compared with the current lower target AUC of 60 mg·h/L.

RESULTS: Isavuconazole was used in a diverse patient population, including some with non-classical host factors, although the primary underlying condition was a haematological malignancy in 56% of patients. Isavuconazole was used as treatment for IA or invasive mucormycosis in most patients; however, it was also prescribed for infections with non-*Aspergillus* and non-Mucorales species, including *Candida* spp. It was also often prescribed to patients with severe viral pneumonia admitted to intensive care. Overall reasons for selecting isavuconazole are shown in the table. Patients were often switched to isavuconazole after experiencing toxicity on prior azoles. Treatment with isavuconazole was successful in 30/51 (58.8%) patients with available data. The drug was generally well tolerated, although exposure was variable and frequent dosage adjustments were needed. The individual average AUC_{24} over 7 days was higher than the target threshold of 60 mg·h/L in 29/77 (37.7%) patients with available data.

CONCLUSIONS: Real-world clinical experience indicated that isavuconazole was used to treat a diverse patient population and was generally well tolerated. Exposure was variable and dosage adjustments were common.

Reasons for choosing isavuconazole in routine clinical practice

		Prophylaxis (n=28), n (%)	Treatment (n=69), n (%)
First-line treatment	Broad spectrum of action	2 (7.7)	3 (16.7)
	Safety profile	19 (65.4)	10 (55.6)
	Favourable drug–drug interaction profile	8 (30.8)	5 (27.8)
	Other	1 (3.8)	3 (16.7)
Second-line treatment	Intolerance (previous therapy)	-	45 (88.2)
	Salvage therapy	-	6 (11.8)

A GLOBAL PERSPECTIVE OF THE CHANGING EPIDEMIOLOGY OF INVASIVE FUNGAL DISEASE AND REAL-WORLD EXPERIENCE WITH THE USE OF ISAVUCONAZOLE

Medical Mycology, 2024 September 6; 62(9):myae083

AUTHORS: THOMPSON GR 3RD, CHEN SC, ALFOUZAN WA, IZUMIKAWA K, COLOMBO AL, MAERTENS J
CENTRE FOR CORRESPONDENCE: DEPARTMENT OF MEDICINE, DIVISION OF INFECTIOUS DISEASES, UC DAVIS
MEDICAL CENTER, SACRAMENTO, CALIFORNIA, USA

BACKGROUND & AIM: Epidemiological data have shown an increase in the incidence of invasive fungal diseases (IFDs). These are difficult to treat because of resistance to antifungal agents, and are associated with high rates of mortality. Isavuconazole is an advanced generation triazole antifungal agent approved for the treatment of invasive aspergillosis (IA) and mucormycosis (IM) in adults and children. This article reviews the epidemiology of and risk factors for IFD, as well as the safety and efficacy of isavuconazole for IA and IM, and its real-world potential to prevent IFDs.

ARTICLE TYPE: Review.

FINDINGS: The number and type of patients at risk of developing IFDs has increased in recent years, partly due to advances in medical treatment, such as the availability of haematopoietic stem-cell transplantation (HCT) and other treatments that cause immunosuppression. This has led to new at-risk populations, including hospitalized patients with severe influenza, a wider range of haematological malignancies, chronic obstructive pulmonary disease and COVID-19 infection. Other risk factors for IFD include congenital immunodeficiencies, and the use of immunosuppressants to prevent and treat transplant rejection. The risk of IFDs is also increased by tumour necrosis factor- α inhibitors and monoclonal

antibodies used to treat autoimmune conditions. An increasing incidence of IFDs in patients with lymphoproliferative disorders is thought to be due to the use of more intensive treatment, while viral infections such as COVID-19 are also associated with an increased risk.

Isavuconazole has been shown to be active against a number of yeasts, moulds and dimorphic fungi *in vitro* and in animal models, and clinical trials have demonstrated its efficacy and safety in adults with IFD due to *Aspergillus* species or Mucorales. More information about its effects in a wider range of patients has come from real-world studies, including patients with haematological malignancies and several other conditions, as well as those who have failed to respond to previous triazole antifungal therapy. There are not yet sufficient data to support the prophylactic use of isavuconazole or its use against endemic IFD.

Isavuconazole is generally well tolerated, and the most common adverse events are nausea, vomiting and diarrhoea. In a retrospective, real-world study, it was associated with significantly fewer adverse events than voriconazole and amphotericin B. Furthermore, it has a comparatively low risk of drug–drug interactions.

CONCLUSIONS: Current evidence suggests a role for isavuconazole in the treatment of patients at risk of IFD, especially when other antifungal therapies are not suitable.

Diagnosehulp bij vermoeden van invasieve schimmelinfecties

Vraag
nu aan!



Vroege diagnose en tijdig starten van antifungale therapie zijn cruciale stappen in het klinisch management van patiënten met een invasieve schimmelinfectie¹. De interactieve diagnosehulp kan hierbij helpen!

Dr. Jochem Buil; arts-microbioloog in het Radboud umc, en dr. Toine Mercier, hematoloog in het AZ Sint-Maarten en consultant in het UZ Leuven, hebben een handig overzicht ontwikkeld met de volgende thema's uit de diagnostiek: Klinische beelden, risicogroepen, diagnostiek en de toepassingen op klinische situaties aan de hand van 3 patiëntencasussen.

Vraag de diagnosehulp hier aan!

www.diagnosehulpinvasieverschimmels.nl



Diagnosticeren vraagt een multidisciplinaire aanpak met de patiënt centraal.
De diagnosehulp ondersteunt hierbij.



1. Cornely OA et al. Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease Mycoses 2011; 54(5): e449-455